Lakefront Biotherapeutics NV current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of January 2022. The filing, dated January 27, 2022, serves to incorporate by reference a press release issued on January 26, 2022 (Exhibit 99.1). Galapagos NV is a foreign private issuer headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.

Key Financial Metrics

The provided filing text does not contain specific financial data. It acts as a conduit for a press release and does not include revenue, profit, cash flow, margins, debt, or liquidity figures. No financial metrics are disclosed in this document.

Material Changes

The filing text does not describe material changes in financial position or operations. It solely references the issuance of a press release on January 26, 2022, the content of which is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that quotes from Dr. Raj Parekh, Mr. Onno van de Stolpe, and Dr. Paul Stoffels contained in the attached press release are not incorporated by reference into the company's Registration Statements.

Investor Verification Checklist

  • Verify the actual content of the press release dated January 26, 2022 (Exhibit 99.1), as the summary text does not detail the announcement.
  • Confirm the registrant name is Galapagos NV, correcting the metadata discrepancy regarding "Lakefront Biotherapeutics NV."
  • Review the company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.
  • Check the Registration Statements (Forms F-3 and S-8) referenced in the filing for updated prospectus information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.